RICHMOND, Va. (WRIC) — According to the Centers for Disease Control and Prevention (CDC), Influenza B-positive tests have risen from 0.12% to 0.36% from January to the last week of March in the United ...

Schools have been advised to notify the nearest district health office in the event of an increase in cases and to isolate students.

A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...

In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement According to GSK, the data demonstrated positive ...

The U.S. Food and Drug Administration (FDA) just issued its first emergency use authorization for an at-home test that can tell users if they have either the flu, COVID-19, or both. The decision on ...

Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine ...

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program 12.09.2024 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement.